Akero Therapeutics AKRO Stock
Akero Therapeutics Price Chart
Akero Therapeutics AKRO Financial and Trading Overview
| Akero Therapeutics stock price | 54.65 USD |
| Previous Close | 54.33 USD |
| Open | 54.87 USD |
| Bid | 51.61 USD x 1000 |
| Ask | 52.3 USD x 1000 |
| Day's Range | 51.9 - 54.87 USD |
| 52 Week Range | 21.34 - 58.4 USD |
| Volume | 881.4K USD |
| Avg. Volume | 1.62M USD |
| Market Cap | 4.15B USD |
| Beta (5Y Monthly) | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.3 USD |
AKRO Valuation Measures
| Enterprise Value | 3.6B USD |
| Trailing P/E | N/A |
| Forward P/E | -12.254118 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.828286 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -11.764 |
Trading Information
Akero Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.16 |
| 52-Week Change | 90.07% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 58.4 USD |
| 52 Week Low | 21.34 USD |
| 50-Day Moving Average | 50.04 USD |
| 200-Day Moving Average | 40.02 USD |
AKRO Share Statistics
| Avg. Volume (3 month) | 1.62M USD |
| Avg. Daily Volume (10-Days) | 999.38K USD |
| Shares Outstanding | 79.72M |
| Float | 66M |
| Short Ratio | 3.84 |
| % Held by Insiders | 1.36% |
| % Held by Institutions | 109.31% |
| Shares Short | 7.75M |
| Short % of Float | 10.00% |
| Short % of Shares Outstanding | 9.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.51% |
| Return on Equity (ttm) | -27.92% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -306329504 USD |
| Net Income Avi to Common (ttm) | -269440992 USD |
| Diluted EPS (ttm) | -3.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 686.29M USD |
| Total Cash Per Share (mrq) | 8.61 USD |
| Total Debt (mrq) | 36.23M USD |
| Total Debt/Equity (mrq) | 3.34 USD |
| Current Ratio (mrq) | 16.804 |
| Book Value Per Share (mrq) | 13.604 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -262631008 USD |
| Levered Free Cash Flow (ttm) | -177472752 USD |
Profile of Akero Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 601 Gateway Boulevard |
| ZIP | 94080 |
| Phone | 650 487 6488 |
| Website | https://akerotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 69 |
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Q&A For Akero Therapeutics Stock
What is a current AKRO stock price?
Akero Therapeutics AKRO stock price today per share is 54.65 USD.
How to purchase Akero Therapeutics stock?
You can buy AKRO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akero Therapeutics?
The stock symbol or ticker of Akero Therapeutics is AKRO.
Which industry does the Akero Therapeutics company belong to?
The Akero Therapeutics industry is Biotechnology.
How many shares does Akero Therapeutics have in circulation?
The max supply of Akero Therapeutics shares is 82.32M.
What is Akero Therapeutics Price to Earnings Ratio (PE Ratio)?
Akero Therapeutics PE Ratio is now.
What was Akero Therapeutics earnings per share over the trailing 12 months (TTM)?
Akero Therapeutics EPS is -3.75 USD over the trailing 12 months.
Which sector does the Akero Therapeutics company belong to?
The Akero Therapeutics sector is Healthcare.
Akero Therapeutics AKRO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23613.31 USD — |
+0.22
|
3.54B USD — | 23527.97 USD — | 23621.72 USD — | — - | 3.54B USD — |
| US Tech Global Select Market Com NQGS | 11566.45 USD — |
+0.21
|
— — | 11525.25 USD — | 11570.56 USD — | — - | — — |
| US Tech Biotechnology NBI | 5843.74 USD — |
+0.69
|
— — | 5812.05 USD — | 5851.25 USD — | — - | — — |
| US Tech Health Care IXHC | 1212.11 USD — |
+0.55
|
— — | 1206.25 USD — | 1213.6 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2677.67 USD — |
+0.4
|
— — | 2663.83 USD — | 2679.59 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}